Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Stopped Internal decision, study will be replaced with a larger monotherapy trial

Conditions

• Neoplasms

Interventions

• DRUG: GSK3377794
• DRUG: Pembrolizumab
• DRUG: Fludarabine
• DRUG: Cyclophosphamide

Sponsor

GlaxoSmithKline

Collaborators

• [object Object]